US 12,186,383 B2
Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
Jonathan R. Lai, Dobbs Ferry, NY (US); Jose Quiroz, Bronx, NY (US); Ryan Malonis, Bronx, NY (US); and Margaret Kielian, Dobbs Ferry, NY (US)
Assigned to Albert Einstein College of Medicine, Bronx, NY (US)
Appl. No. 16/972,077
Filed by Albert Einstein College of Medicine, Bronx, NY (US)
PCT Filed Jun. 6, 2019, PCT No. PCT/US2019/035828
§ 371(c)(1), (2) Date Dec. 4, 2020,
PCT Pub. No. WO2019/236875, PCT Pub. Date Dec. 12, 2019.
Claims priority of provisional application 62/681,247, filed on Jun. 6, 2018.
Prior Publication US 2022/0265806 A1, Aug. 25, 2022
Int. Cl. A61K 39/12 (2006.01); A61K 33/242 (2019.01); A61K 39/42 (2006.01); A61P 31/14 (2006.01); C07K 16/10 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 33/242 (2019.01); A61K 39/42 (2013.01); A61P 31/14 (2018.01); C07K 16/1081 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/525 (2013.01)] 26 Claims
 
1. An anti-Chikungunya (CHIKV) antibody or CHIKV-binding fragment thereof, wherein said antibody or fragment thereof comprises:
(1) a heavy chain comprising (i) a CDR1, CDR2, and CDR3 as set forth in any one heavy chain row of Table 1;
(2) and a light chain comprising (i) a CDR1, CDR2, and CDR3 as set forth in any one light chain row of Table 1, which light chain row belongs to the same laboratory designated antibody as the heavy chain row in (1).